The US Food and Drug Administration (FDA) has approved Kisqali (ribociclib) in combination with an aromatase inhibitor (AI) ...
An FDA approval has officially lifted the curtain on a blockbuster market showdown between Novartis and Eli Lilly in early ...
Kisqali generated $2bn in sales last year, with broader approvals forecasting sales of over $8bn by 2030, per GlobalData ...
Verzenio was approved for a similar adjuvant indication last year, having been used for a couple of years only in patients ...
Zacks.com on MSN1d
Pharma Stock Roundup: FDA Approvals for LLY, MRK, AZN & JNJ DrugsThis week, the FDA approved Eli Lilly’s LLY eczema drug, Ebglyss (lebrikizumab), and the expanded use of Novartis’ NVS ...
Kisqali has been FDA-approved with an aromatase inhibitor as postsurgical treatment for some with early breast cancer at a ...
Women with early stage breast cancer may now take Kisqali, a medication already approved for advanced disease.
Medpage Today on MSN4d
FDA Expands Approval of Ribociclib to Early Breast CancerThe drug joins abemaciclib (Verzenio) as approved CDK4/6 inhibitors in this setting, but the broader indication for ...
Unlike rival CDK 4/6 inhibitor abemaciclib, patients don't need to be lymph-node positive to receive ribociclib after surgery ...
The US FDA has approved Kisqali (ribociclib) for treating early-stage breast cancer in combination with hormone therapy. It targets high-risk HR-positive, HER2-negative stage II and III patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback